Riskpilot← Back to searchSign inGet full accessAlder Therapeutics AB
ABActiveOrg 5593552762Vasagatan 28Research and experimental development on natural sciences and engineering · NACE 7210Est. 20211 employees
Revenue 2024
SEK 0
EBITDA margin
—
+57% vs 2023
Equity ratio
35.8%
Financial strength
Net profit 2024
SEK -7,9M
+55% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -7,8M | +57% |
| Net profit | SEK -7,9M | +55% |
| Total assets | SEK 14,7M | +4% |
| Equity | SEK 5,3M | -60% |
| Employees | 1 | — |
Legal name
Alder Therapeutics AB
Org number
5593552762
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 december 2021
Share capital
SEK 145 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder Styrelsen ska bestå av 4 styrelseledamöter och 0 styrelsesuppleanter.
Company purpose
Bolaget ska bedriva utveckling av läkemedel och därmed förenlig verksamhet.
Address
Vasagatan 28
Email
kristian@aldertx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 216 | 20 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −3 570 | −17 909 | −7 758 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −3 570 | −17 909 | −7 758 |
| Net financials | 21 | 321 | −177 |
| Profit before tax | −3 549 | −17 589 | −7 935 |
| Tax | −0 | −0 | −0 |
| Net profit | −3 549 | −17 589 | −7 935 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 17 311 | 14 128 | 14 680 |
| Equity | 16 414 | 13 187 | 5 252 |
| Long-term debt | 0 | 0 | 8 000 |
| Short-term debt | 897 | 941 | 1 427 |
| Total debt | 897 | 941 | 9 427 |
EBITDA margin
-775800000.0%
This company
15.8%
Market median
-4910126682% vs market
20222024
Equity ratio
35.8%
This company
38.2%
Market median
+6% vs market
20222024
Return on equity
-151.1%
This company
18.4%
Market median
-921% vs market
20222024
Net profit margin
-793500000.0%
This company
8.1%
Market median
-9796296396% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
1.80×
This company
0.62×
Market median
-190% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CO Audit | Audit | 2022 |
KK Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2026 | |
| Former (3) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2026 | |
| Board of Directors | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Alder Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Olov Strömberg | Audit | 0 companies |
| Karl Kristian Tryggvason | Chief Executive Officer | 0 companies |
| Eva Margareta Eljans | Deputy Board Member | 0 companies |
| Snickar Karl Johan Tobieson | Board of Directors | 0 companies |
| Ted Ingemar Jakob Fjällman | Board of Directors | 0 companies |
| Hans Fredrik Mattsson | Chairman | 0 companies |
| Karl Ola Elmqvist | Board of Directors | 0 companies |
| Anita Helena Berggren | Board of Directors | 0 companies |